Arcus Biosciences, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $8.00M.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $142.00M, a 37.72% decline year-over-year.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $228.00M.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $5.00M.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for fiscal 2025 was $429.00M, a 88.16% increase from fiscal 2024.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for fiscal 2024 was $228.00M, a 812.00% increase from fiscal 2023.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for fiscal 2023 was $25.00M.
- Arcus Biosciences, Inc. stock issued during period, value, new issues for fiscal 2021 was $220.00M, a 32.52% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $429.00M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $8.00M 10-Q · filed 2025-10-28 | |
| 2025-03-31 | $142.00M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $228.00M 10-K · filed 2026-02-25 | |
| 2024-03-31 | $228.00M 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $25.00M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $5.00M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $20.00M 10-Q · filed 2024-11-06 | |
| 2021-12-31 | $220.00M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $326.00M 10-K · filed 2023-02-28 | |
| 2020-06-30 | $326.25M 10-Q · filed 2021-11-08 | |
| 2018-12-31 | $124.73M 10-K · filed 2021-02-25 | |
| 2018-03-31 | $124.72M 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |